Protagonist Therapeutics, Inc
PTGX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001377121
In the last 90 days, Protagonist Therapeutics, Inc insiders filed 0 open-market purchases and 2 sales; 346 institutions reported holding it in 13F filings for Q2 2026, worth $9.30B in total; Duquesne Family Office is the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Protagonist Therapeutics, Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 2 filings
- 1 insider, $33.1M in total
- Insiders trading
- 1
- Net value
- −$33.1M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Protagonist Therapeutics, Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Patel Dinesh V PH D | President and CEO | 522,968 | Sep 10, 2026 | 10 |
| Waddill William D. | Director | 7,825 | Jun 25, 2026 | 6 |
| Giraudo Bryan | Director | 12,695 | May 11, 2026 | 2 |
| Ali Asif | Chief Financial Officer | 59,003 | Apr 21, 2026 | 5 |
| Selick Harold E | Director | 60,845 | Mar 27, 2026 | 3 |
| Molina Arturo MD | Chief Medical Officer | 84,115 | Mar 27, 2026 | 5 |
| Williams Lewis T | Director | 7,825 | Feb 18, 2026 | 2 |
| O'Dowd Sarah A | Director | 7,825 | Jan 6, 2026 | 1 |
| Gupta Suneel | Chief Development Officer | 267,433 | Nov 27, 2024 | 0 |
| Swisher Daniel N JR | Director | – | Oct 30, 2023 | 0 |
| Noonberg Sarah B. | Director | – | Jan 18, 2023 | 0 |
| Liu David Y | Chief R&D Strategy Officer | 167,590 | Nov 17, 2022 | 0 |
| Kalkofen Donald A. | Chief Financial Officer | 18,521 | Feb 17, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 4, 2024 (view filing) | Nov 15, 2023 | 50 daysLate | Molina Arturo MDChief Medical Officer | SSale | −1.85K | $16.24 | −$30.0K | −7.6%22.5K after | |
| Dec 15, 2023 (view filing) | Dec 13 | 2 days | Patel Dinesh V PH DPresident and CEO | SSale | −75.0K | $20.08 | −$1.51M | −12.3%534.3K after | 10b5-1 |
| Dec 23, 2021 (view filing) | Dec 21 | 2 days | Patel Dinesh V PH DPresident and CEO | SSale | −15.0K | $32.14 | −$482.1K | −3.0%477.2K after | |
| Aug 19, 2021 (view filing) | Aug 17 | 2 days | Liu David YChief Scientific Officer | SSale | −14.8K | $47.56 | −$702.9K | −20.2%58.3K after |